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Abstract
Dysbiotic states of gut ecology can be altered directly by transplantation of fecal preparation from healthy donors to patients with therapeutic intent. This paper 
assesses this fecal microbiota transplantation (FMT) in two respects: (1) the bacterial shifts in patient microbiomes with FMT and (2) clinical outcomes and 
variables of FMT. The PubMed database was searched using the MeSH terms “Feces/microbiology,” “Microbiota,” and “Transplantation.” Thirteen papers found 
examined clinical outcomes and variables of FMT, and eight assessed metagenomic data and bacterial composition in the peri-FMT period. FMT was reported 
to have high cure rates in Clostridium difficile infection (CDI), generally increased levels of members of the phyla Bacteriodetes and Firmicutes, and decreased 
levels of members of Proteobacteria. Therapeutic FMT alters bacterial composition from a dysbiotic state pre-FMT to a healthy commensal state post-FMT in CDI 
patients, but further studies are necessary to understand its role in the treatment of other diseases.
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Introduction
Fecal microbiota transplantation (FMT) is an increasingly com-
mon therapeutic procedure in which fecal material is taken 
from a healthy donor and transferred to a recipient with the 
intention of beneficially altering the composition of bacteria in 
the recipient’s gut. While interest in FMT has risen because of 
its simplicity and efficacy, the emergence of modern molecular 
techniques has improved and reshaped the understanding of 
FMT. Specifically, the advent of 16S bacterial specific ribosomal 
RNA sequencing, driven by the Human Microbiome Project, has 
allowed for the elucidation of the composition of intestinal bac-
teria and their dynamics, particularly in relation to disease.1
The understanding of the role of intestinal bacteria has shifted 
in the last two decades from passive by-standers to commen-
sal maintainers of homeostasis and health. Numerous studies 
have demonstrated associations between intestinal microbiome 
composition and diseases, both intestinal and extra-intestinal. 
Among these are bacterial colonic overgrowth, metabolic deran-
gements, auto-immune and inflammatory disorders, psychiatric 
and neurological disorders, and cardiovascular disorders.1
However, despite the establishment of intestinal dysbioses in 
such a broad spectrum of disease, of these conditions, only a 
handful have been treated with FMT and assessed systemati-
cally in patients. Notably, patient data have been published 
related to recurrent Clostridium difficile colitis, metabolic sy-
ndrome, ulcerative colitis, Crohn’s disease, chronic fatigue sy-
ndrome, thrombocytopenic purpura, Parkinson’s disease, and 
multiple sclerosis.2-9 The size and scope of the studies and re-
ports involved are limited, however, and of the disorders listed, 
Clostridium difficile infection (CDI) has had the most clinical 
data establishing its credibility as a standard therapy.
As the number of clinical trials and patient data continue to 
grow, the compositional landscape of the flora involved in the 
normal gut and its pathological states have become more re-
fined. Many of the more recent studies involving FMT have 
characterized rapid, dynamic shifts in bacterial composition 
charted through time. The increasing prevalence of FMT has 
allowed other variables to be more thoroughly examined as 
well; FMT in immunocompromised patients and methods of 
FMT have both been assessed. This paper will examine both the 
metagenomic data gathered from published articles assessing 
therapeutic FMT and the clinical efficacy of FMT in the currently 
documented literature. Ultimately, the particular bacterial stra-
ins associated with a ‘healthy’ microbiome and a pathological, 
dysbiotic microbiome will be compared with regards to FMT 
for various disease states through time and between donor 
and recipient. The outcomes of therapeutic FMT will also be 
discussed, and documented variables in the literature will be 
assessed for a pattern of clinical success. 
Restated, this paper seeks to answer the simple questions: “How 
does FMT affect gut bacteria? How well does it work? What makes 
it work better?” These questions are fundamental in establishing 
the basis of FMT therapy as a viable procedure and will be ad-
dressed systemically by reviewing the current relevant literature. 
While this analysis of the literature gives insight into the current 
evidence and understanding of FMT, it is worth mentioning that 
our understanding of the mechanisms and the complexities of 
the microbe-gut interaction remains relatively nascent.
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Search Strategy and Selection Criteria
Goals of search
The goal of the search strategy used was to identify two types of 
articles in the PubMed database: those with published clinical 
data regarding the efficacy of FMT therapeutically and those with 
metagenomic data demonstrating shifts in bacterial composition 
associated with the use of FMT. Since the aim of this paper was 
to answer questions regarding variables about the FMT procedu-
re, care was taken to filter for publications specifically assessing 
FMT rather than profiling microbiota associations alone.
Search terms
The emerging nature of therapeutic FMT warranted additio-
nal search methods to procure all relevant literature. Because 
“FMT” (or “Fecal Microbiota Transplantation”) is not a unique 
MeSH term, other MeSH terms were initially used to maximize 
inclusion of desired articles and minimize inclusion of unrela-
ted articles. The MeSH terms used were: “Feces/microbiology,” 
“Microbiota,” and “Transplantation;” these terms identified 4 
desired articles when filtered for clinical trials only searching 
the entire PubMed database.10-13
Selection and analysis
After identification of these major articles, additional articles 
were selected by two means. The first method of finding ad-
ditional articles was by reviewing the citations in each paper. 
Papers that met the inclusion criteria of being an FMT-related 
clinical trial published from 2010 to present were included. The 
second method used the “Cited by” option in the PubMed da-
tabase to identify papers that cited each of the papers inclu-
ded, and the inclusion criteria were again applied.
Two exceptions to these criteria were made. Because of their 
size and scope, two systematic reviews of FMT were included. 
The first was published in November 2011 by Gough, et al., 
and included 27 case series and reports of outcomes of FMT 
in CDI.14 The second was published in August 2014 by Colman, 
et al., and included 18 case series and reports of FMT in IBD.5
Each paper included was analyzed for the data provided that 
addressed the original research goals. Two evidence tables 
were compiled from this; one detailing the clinical aspects 
of FMT and the other detailing the microbiome compositional 
analysis in the peri-FMT period. When the original papers did 
not provide the level of detail required to properly compare 
data, their supplementary material was assessed for the re-
levant information and added to the tables. Supplementary 
data was re-analyzed to formulate similar data presentation 
from papers.
Results
Ultimately, 4 papers were returned with the initial MeSH term 
search, and 17 papers were included through indirect citation, 
with a total of 21 papers assessed. Of these, 19 met the inclu-
sion criterion. Thirteen papers were related to the clinical effi-
cacy of FMT, and 8 papers were related to the effects of FMT on 
the composition of patients’ microbiomes. The types of papers 
assessed are categorized in Table 1.
Clinical aspects of fecal microbiota transplantation
Transplantation of fecal material from donor to recipient has 
been clinically reported in a variety of capacities. The exact me-
thods of FMT, sample selection, patient selection, and efficacy 
are all variables of the procedure that have been assessed. 
Recent papers have examined these variables of FMT for the 
treatment of CDI as well as inflammatory bowel disease (IBD).
Fecal microbiota transplantation in recurrent Clostridium 
difficile infection
Cure rates using fecal transplantation for recurrent Clostridium 
difficile infection
Until recently, FMT was reported in the literature only through 
case series as successful in the treatment of CDI. The first ran-
domized control trial testing was published in January 2013, 
and it validated what had been established through interven-
tional observation: FMT is as effective, if not more effective, for 
treating CDI as traditional antibiotic therapy. The study (n=43) 
by van Nood, et al., demonstrated that FMT was able to cure 
CDI with an overall rate of 94%, while conventional vancomycin 
therapy and vancomycin therapy with bowel lavage fell short, 
with cure rates of 31% and 23%, respectively.15
Virtually every case series published prior to this trial regarding 
CDI and FMT has reported cure rates in a similar range. A case 
series charting the long term outcomes of FMT in CDI patients had 
an overall cure rate of 98% (n=77), and another case series exami-
ning the outcomes of FMT in immunocompromised patients had 
an overall cure rate of 89%.13,16 Other studies examining procedural 
variables of FMT, such as a combined small and large intestinal 
transplantation (n=27), and a frozen pill-based delivery of FMT 
(n=20) had success rates of 100% and 90%, respectively.10,17 Prior to 
these studies, Gough, et al., performed a systematic review of all 
case series and reports pooled data into a meta-analysis of repor-
ted FMTs, finding that 92% of patients indexed were successfully 
treated with FMT for CDI with one or multiple transplantations.13
Protocol of transplantation for recurrent Clostridium difficile infection
The concept of FMT involves delivery of donor bacteria to a reci-
pient. The protocol of this delivery has not been standardized, 
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Level Description
Level 0 Preclinical studies– including experimental studies and animal models
Level 1 Randomized controlled trials
Level 2 Non-randomized controlled trial – a prospective (pre-planned) study with a predetermined eligibility criteria and outcome measures
Level 3 Observational studies with controls- includes retrospective, case-control studies, and cohort studies
Level 4 Observational studies without controls – includes cohort studies without controls, case series without controls, case studies without 
controls
Level 5 Systematic reviews and meta-analyses
Table 1. Article types and numbers.
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and techniques vary widely. While data have been published 
vetting the efficacy of fecal transplantation via nasoduodenal 
tube, combined colonoscopy, encapsulated oral formulation, 
and enema for the treatment of CDI, thus far only one rando-
mized control trial has been conducted to evaluate the opti-
mal route of fecal administration.10,15,17,18 In this study (n=20) 
by Youngster, et al., outcomes of FMT performed by delivery 
via nasogastric (NG) tube and colonoscopy were compared in 
an open-label, randomized trial.18 Both methods had high cure 
rates of 80% and 100%, respectively, with the major limitation 
being the sample size. The same research group further establi-
shed efficacy of an oral, encapsulated FMT, with a cure rate of 
90% in a similarly small sample size of 20 patients.10
Other parameters of the FMT protocol have not been as tho-
roughly examined, but have been mentioned by clinical inves-
tigators as potentially having an effect on clinical outcomes.14 
Sample preparation of donor feces generally involves dilution 
and filtration; homogenization in a blender system was not 
reported to alter microbiome composition of the sample.17 Criti-
cally, the optimal volumes and concentrations of FMT have yet 
to be established, as a failure of colonization with low amounts 
could possibly lead to a failure of FMT therapy.
Candidates for therapeutic fecal transplantation for recurrent 
Clostridium difficile infection
Fecal microbiota transplantation has been shown to be large-
ly effective in the treatment of recurrent C. difficile infection. 
Largely, adult populations were treated, with the mean age of 
these patients in Table 2 being 55.9 (SD=18.4). More females 
(n=351) than males (n=242) were treated for CDI with FMT 
in the papers included. However, there were no studies that 
established any meaningful variable to successful FMT the-
rapy for CDI. Variables such as age, sex, previous recurrence 
of CDI, antibiotic regimen, and proton pump inhibitor thera-
py were examined in most papers. One study found some 
association between patient-reported health scores and FMT 
outcomes.10 
Russell, et al., reported a case series of pediatric patients 
(n=10) who underwent FMT for the treatment of CDI.19 Of the 7 
patients with uncomplicated CDI, a cure rate of 100% was re-
ported. In 3 patients, CDI was compounded on by IBD in which 
2 of these patients were cured, but the third was refractory to 
treatment. Overall, the authors noted that while FMT aided in 
the resolution for CDI, the underlying IBD was unaffected.
Another critical variable assessed by one study (n=80) was the 
immune status of patients undergoing FMT.16 Since the funda-
mental nature of fecal transplantation requires the introduc-
tion of foreign organisms into a host, the theoretical compli-
cation of infection is possible. It is speculated that this risk 
could be higher in patients with compromised immune status. 
Kelly, et al., examined outcomes in a population of patients 
that included patients with solid organ transplants on immu-
nosuppressive therapy, patients with HIV/AIDS, patients on 
systemic immunosuppressants for inflammatory conditions 
such as IBD and rheumatoid arthritis, patients with chronic, 
end-stage diseases such as cirrhosis, ESRD, COPD, and can-
cers, many of whom were receiving anti-neoplastic therapy. 
FMT in these patients had an overall cure rate of 89% for CDI. 
The other major outcome measured to assess the safety of 
the procedure in this population was a number of serious 
adverse events, including unplanned hospitalizations, dea-
ths, life-threatening experiences, and other important medical 
events. Fifteen percent of the study participants experienced 
a serious adverse event, and two patients died. However, the 
authors stressed the critical nature of these patients and that 
adverse events that occurred in patients receiving FMT were 
not related to the procedure. Due to the similar cure rate to 
previous studies and the nature of complications observed 
in patients, the authors concluded that immunocompromised 
patients were at no risk of complication and that FMT was 
safe in such a population.16
Fecal microbiota transplantation in inflammatory bowel disease
IBD is a term used to describe two inflammatory conditions of 
the gastrointestinal system, ulcerative colitis (UC) and Crohn’s 
disease. While fairly high cure rates of FMT therapy have been 
reported for CDI, results of FMT in IBD have been mixed. Clinical 
data supporting the use of FMT in IBD is limited. To date, two 
published randomized trials have examined FMT in IBD.20,21 One 
systematic review pooling data from 18 studies was published 
in August 2014, which included the data from the mentioned 
randomized control trial.5
Outcomes of fecal transplantation in patients with inflammatory 
bowel disease
Colman, et al., pooled data from 18 case series and reports to 
systematically review outcomes of IBD patients receiving FMT.5 
Included in this assessment of the literature are three studies 
in Table 1, one randomized control trial that is still underway 
with preliminary results published and two case series exami-
ning pediatric populations, and two studies from Table 3.4,20,22-24 
The systematic review included data published up until May 
2014, pooling data from 119 patients suffering from IBD. Statis-
tical analysis performed on the data found that 22% of Crohn’s 
patients and 60.5% of UC patients achieved clinical remission. 
Overall, 45% of patients with IBD in the 18 included studies of 
the review achieved remission.
The first randomized control trial (n=70) evaluating the outcomes 
of FMT against a placebo in patients with UC were conducted 
by Moayyedi, et al., in 2015. Rates of remission and changes in 
the severity of UC were assessed. The protocol involved weekly 
infusion of fecal material from healthy donors, and the outcomes 
were in line with what has thus far been reported in the literature 
regarding remission achieved by FMT in IBD. FMT did not have any 
advantage over water enema in severity reduction, but had some 
success in disease remission. Twenty four percent of patients who 
had received weekly fecal transplantations for 6 weeks had clini-
cally achieved remission at week 7, whereas only 5% of patients 
who had received a water enema achieved remission.20
The second randomized control trial (n=50) by Rossen, et al., 
published in July 2015 had similar findings and parameters to 
the aforementioned UC randomized control trial. The rates of 
remission and clinical response, defined through improvement 
in the Simple Clinical Colitis Index (SCCAI) were addressed. The 
protocol involved two infusions of either autologous or donor 
fecal preparation, with the second infusion given three weeks 
after the first. Follow-up at 6 and 12 weeks after FMT revealed 
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Date, Design, Level, 
(n), First author
Inclusion criteria Objective Measures Findings
Systematic Review 
of Intestinal 
Microbiota Trans-
plantation (Fecal 
Bacteriotherapy) 
for Recurrent 
Clostridium difficile 
Infection.14
November 2011.
Systematic literatu-
re review.
Level 5
n = 317
Gough, Ethan
Publications docu-
menting infusion of 
stool from a healthy 
donor into an 
unhealthy human 
subject for CDI.
No duplicate co-
horts included.
Mean age: 53
F: 193, M: 124
Perform a full 
systematic review 
of all available FMT 
procedures for CDI 
(27 case series and 
reports), which, 
at the time of pu-
blication, was not 
before assessed.
• Failure: continued occurrence or 
recurrence of disease after trans-
plantation.
• Cessation: complete cessation of 
symptoms or diagnostic verification 
of no disease.
• Relapse: resolution with return of 
symptoms.
• Deaths, due to illness unrelated 
illness as reported by authors.
• FMT procedure parameters.
92% of patients treated had resolution; 89% 
with single treatment and 5% with treatment 
after failure or relapse.
11% had a relapse event.
Better outcomes observed with:
• Transplant from a related donor.
• Rectal catheter route.
• Antibiotics and lavage before FM.
o This also had a high relapse rate.
• Larger (>500 mL) FMT used for transplan-
tation.
Long-Term 
Follow-Up of 
Colonoscopic Fecal 
Microbiota Trans-
plant for Recurrent 
Clostridium difficile 
Infection.16
July 2012.
Retrospective case 
series.
Level 2
n = 77
Brandt, Lawrence J
Recurrent C. difficile 
colitis refractory to 
medical therapy, 
FMT therapy.
Mean age: 65
F: 56, M: 21
Determine long-
term cure rates 
of FMT in patients 
with C. difficile 
infection; mean of 
follow up was 17 
months.
Assess antibiotic 
use post-FMT.
• Primary cure: resolution of diarr-
hea within 90 days.
• Secondary cure: resolution with 
additional antibiotics with or 
without repeat FMT.
• Patient-reported diarrhea, abdo-
minal pain, fatigue, weight change.
Primary cure in 70 of 77 patients (91%), secon-
dary cure in 76 of 77 patients (98%).
Patients reported improvement and resolution 
in all survey parameters.
Two patients reported improvement in other 
conditions and 4 patients reported develop-
ment of new diseases.
30 of 77 patients required antibiotic use 
unrelated to CDI after FMT; of these 8 had a 
recurrence of CDI.
Duodenal Infusion 
of Donor Feces for 
Recurrent Clostri-
dium difficile.15
January 2013.
Randomized  con-
trol trial, open-label 
(NTR1177).
Level = 2
n = 43, 2 lost
van Nood, Els
Patients with CDI 
defined as at least 
one relapse while 
using antibiotic the-
rapy and positive 
toxin assay.
Mean age: 69.6
F: 18, M: 24
Compare three 
protocols for treat-
ment of recurrent 
CDI: nasoduodenal 
FMT, antibiotic the-
rapy, and antibiotic 
therapy with bowel 
lavage.
Assess diversity of 
microbiome.
• Cure: resolution of diarrhea 
without relapse within 10 weeks 
of FMT.
• Simpson reciprocal index of 
diversity.
• 13/16 (81%) of patients in the FMT group were 
cured with one FMT; 2/3 (66%) patients requiring 
more than one FMT were cured after relapse.
o Overall cure rate for FMT was 15/16 (94%).
• 4/13 (31%) of patients in vancomycin antibio-
tic therapy group were cured.
• 3/13 (23%) of patients were cured in the 
vancomycin-lavage arm.
• Microbiome diversity was low pre-FMT and 
resembled donor’s high diversity after FMT.
Safety, Tolerability, 
and Clinical Res-
ponse After Fecal 
Transplantation in 
Children and Young 
Adults With Ulcera-
tive Colitis.22
June 2013.
Case series.
Level 2
n = 10
Kunde, Sachin
Patients with ulce-
rative colitis (UC), 
with an UC index 
between 15 and 65; 
this excluded cases 
of fulminant colitis 
and C. difficile 
colitis.
Mean age: 15.2
F: 4, M: 6
Evaluate safety 
and tolerability 
of FMT (with no 
bowel preparation) 
in a pediatric 
population.
Assess effect of 
FMT on clinical 
severity of UC.
• Adverse events.
• Serious adverse events.
• Tolerance, defined as ability to 
retain enema.
• Clinical response in terms of UC 
index activity - questionnaire.
Adverse events reported included abdominal 
pain, bloating, diarrhea, blood in stool, fatigue, 
and fever.
• No serious adverse events were noted.
• One patient had intolerance (and was 
excluded from further therapy).
78% of patients showed clinical response in 1 week.
66% maintained this improvement at 1 month.
33% of patients had clinical remission after a week.
Overall, median UC index activity decrease was 
statistically significant (p=0.03), and the overall 
level of improvement did not correlate with the 
initial level of UC index activity.
Fecal Transplant 
for Recurrent Clos-
tridium difficile In-
fection in Children 
with and without 
Inflammatory 
Bowel Disease.19
May 2014.
Case series.
Level 2
n = 10
Russell, George
Pediatric patients 
with recurrent C. 
difficile colitis; 3/10 
patients had IBD.
Mean age: 7.8
F: 4, M: 6
Assess the efficacy 
of FMT in a pe-
diatric population 
with IBD.
• Relapse rate
• Adverse events
• Time to relapse
• Follow-up
Patients without IBD (7/7) had 100% resolution.
2/3 (67%) of patients with IBD had resolution 
of C.difficile colitis, though underlying IBD 
activity was not affected.
No serious adverse events were noted, though:
• Short term, self-resolving complications included 
abdominal pain, bloating, cramping, and diarrhea.
• One patient experienced mucoid stools for 2 
weeks after FMT.
Fecal Microbiota 
Transplant for Relap-
sing Clostridium di-
fficile Infection using 
a Frozen Inoculum 
from Unrelated Do-
nors: a Randomized, 
Open-label, Contro-
lled Pilot Study.18
June 2014.
Randomized control 
trial.
Level 1
n = 20
Youngster, Ilan
Patients with CDI 
with at least 3 
relapses after anti-
biotic treatment,
Mean age: 54
F: 11, M: 9
Compare the 
clinical efficacy 
of FMT delivered 
by nasogastric 
(NG) tube and 
colonoscopy.
• Cure: cessation of diarrhea for at 
least 8 weeks.
• Relapse rate.
• Adverse events.
• Self-reported health questionnaire.
• Shannon diversity index.
In the colonoscopy group, 6/10 (60%) of 
patients were cured with one FMT.
• Overall cure rate for colonoscopy: 100%.
In the NG tube group, 8/10 (80%) were cured with one FMT.
• Overall cure rate for NG tube: 80%.
Of the remaining 6 patients requiring a second FMT, 
one refused further FMT and 5 elected to have a 
second FMT via NG tube; of these, 4 were cured.
Health score was reported higher in colonoscopy patients.
Diversity was unaffected by route of FMT.
Fecal Microbiota 
Transplant for 
Treatment of 
Clostridium difficile 
Infection in Immu-
no-compromised 
Patients.13
July 2014.
Retrospective case 
series.
Level 2
n = 80
Kelly, Colleen R
Compromised 
immune status.
• IBD with immu-
no-suppressant 
therapy.
• Solid organ 
transplant reci-
pients.
• Severe or end 
stage chronic 
conditions.
o HIV/AIDS.
o Cancer.
o Others.
Mean Age: 53
F: 38, M: 42
Assess the long 
term cure rates 
and adverse events 
of FMT in immu-
no-compromised 
patients with C. 
difficile infection; 
mean follow up 
was 11 months.
Parameters within 
12 weeks.
• Mortality.
• Hospitalizations.
• Adverse events (AEs): any 
untoward medical occurrence, 
seemingly causal or not.
• Serious adverse events (SAEs): 
death, life-threatening experience, 
unplanned hospitalization, or 
important medical event.
• CDI recurrence and cure rates.
Resolution in 62 of 80 patients (78%) with sin-
gle FMT; 8 of 12 remaining patients cured with 
second FMT; overall cure rate of 89%.
SAEs seen in 12 patients in 12 weeks.
• Two deaths.
o Due to pneumonia after resolution of 
diarrhea.
o Due to aspiration 1 day after FMT.
• 10 hospitalizations.
o One due to abdominal pain after FMT 
(directly related).
o Four with IBD flares after FMT.
o Other events deemed unrelated.
∏ Cerebrovascular event.
∏ Influenza, no progression.
∏ Catheter infection.
∏ Hip fracture.
∏ Pancytopenia, fever, encephalopathy.
Authors conclude no increased risk of FMT in 
this patient population.
Table 2. Clinical evaluation of fecal microbiota transplantation.
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Fecal Microbiota 
Transplantation 
as Therapy for 
Inflammatory 
Bowel Disease: A 
Systematic Review 
and Meta-Analysis.5
August 2014.
Systematic review.
Level 5
n = 119
Colman, Ruben J
Publications 
assessing FMT in 
the treatment and 
management of IBD.
Age range: 7-64
Perform a full 
systematic review 
of all available FMT 
procedures for IBD 
(18 case series and 
reports included).
• Clinical remission: defined by a 
Mayo score > 2.
• UC outcomes.
• Crohn’s outcomes.
54/119 (45%) of demonstrated remission after 
FMT.
• 22% of UC patients had remission.
• 60.5% of Crohn’s patients had remission.
Efficacy of Com-
bined Jejunal and 
Colonic Fecal Mi-
crobiota Transplan-
tation for Recurrent 
Clostridium difficile 
Infection.17
September 2014.
Prospective case 
series.
Level 2
n = 27
Dutta, Sudhit
Patients with three 
recurrences of C. di-
fficile colitis treated 
with FMT therapy.
Mean age: 64.5
F: 22, M: 5
Measure clinical 
outcomes of FMT 
with a protocol 
involving simul-
taneous delivery 
of transplant to 
both colon and 
jejunum.
• C. difficile toxin.
• Symptomatic relief.
• Time to resolution.
• Body mass index.
• Taxonomic composition of FMT.
• Effect of homogenization of FMT 
sample.
Clinical efficacy
• 27 of 27 patients had resolution of colitis and 
negative toxin 1 to 3 months after FMT.
• 88.2% had resolution of abdominal pain.
• 100% had resolution of bloating.
• 1-3 days were reported for time to resolution.
• Homogenization had no significant effect on 
the composition of microbiota (<0.3% change 
in composition).
• Dual delivery of FMT to jejunum and colon 
was performed with 100% clinical success.
Metagenomic analysis
• Phylum: Firmicutes.
o Lachnospiraceae: increase.
• Phylum: Proteobacteria.
o Enterobacteriales: decrease.
Oral, Capsulized, 
Frozen Fecal Micro-
biota Transplanta-
tion for Relapsing 
Clostridium difficile 
Infection.10
November 2014.
Prospective case 
series.
Level 2
n = 20
Youngster, Ilan
Patients with at 
least 3 recurrences 
of CDI.
Median age: 64.5
F: 9, M: 11
Assess the clinical 
safety of oral, 
encapsulated FMT 
in CDI and deter-
mine its efficacy, 
particularly as an 
alternative to fresh 
stool preparations.
• Resolution of diarrhea without 
relapse.
• FMT-related adverse events.
• Daily bowel movements.
• Self-reported general health sur-
vey score and GI survey score.
Overall, in the 8 week study period, 18/20 
patients achieved a resolution (90%) of their 
CDI-related diarrhea
• 14/20 patients had resolution with adminis-
tration of FMT on first administration.
• 6/20 patients were given a second FMT after 
recurrence of CDI after 7 days; of these 5/6 
had resolution of CDI in the 8-week study 
with one of the 5 have a relapse.
• 1/20 patient had unresolved CDI after 8 weeks.
Secondary outcomes
• Bowel movements decreased from 5/day to 1/day.
• General self-health score improved from 5 to 8.
• GI self-health score improved from 4.5 to 8.
• No variables were associated with FMT 
outcomes other than the pre-FMT general 
self-health score.
• Age, sex, previous recurrence number, anti-
biotic regimen, and gastric acid suppression 
therapy were not associated with outcomes.
Fecal Microbial 
Transplant via 
Nasogastric Tube 
for Active Pediatric 
Ulcerative Colitis.23
January 2015.
Case series.
Level 2
n = 4
Suskind, David
Male pediatric 
patients with active 
UC without C.diffici-
le infection.
Patients were medi-
cated for UC.
Mean age: 14.5
Assess the role of 
FMT via nasogastric 
(NG) tube in UC 
management.
• UC index activity score at follow 
up at 2, 6, and 12 weeks post-FMT.
• Adverse events.
• Serum CRP and stool calprotectin.
2/4 (50%) of patients developed C. difficile 
diarrhea despite being tested prior to FMT 
and despite donor screening for evidence of 
C. difficile; treatment successfully cured these 
patients.
No change in UC index was found in any 
patient 2 weeks after follow up; no change in 
calprotectin or CRP seen.
Authors state no clinical benefit of NG tube.
Findings From a 
Randomized Con-
trolled Trial of Fecal 
Transplantation for 
Patients With Ulce-
rative Colitis.21
July 2015.
Randomized control 
trial.
Level 1
n = 50
Rossen, Noortje
Patients with 
mild to moderate 
ulcerative colitis - 
Simple Clinical Colitis 
Index (SCCAI) ≥ 4, ≤ 
11 - on maintenance 
therapy.
Compare outcomes 
of FMT in UC 
patients  with 
either autologous 
or donor feces with 
follow-up at 6 and 
12 weeks.
• Clinical remission of UC: SCCAI ≤2
• Clinical response defined as 
change in SCCAI ≥1.5.
• Adverse events.
Primary outcome
• Clinical remission in 7/23 (30.4%) patients 
who underwent healthy donor FMT vs 8 of 25 
(32%) patients who underwent autologous FMT.
Secondary outcomes
• Clinical response in 11 of 23 (47.8%) 
patients with donor FMT vs 13 of 25 (52%) 
patients with autologous FMT.
• Adverse events non-significant with sponta-
neous resolution within 2 days of FMT.
Fecal Microbiota 
Transplantation 
Induces Remission 
in Patients With 
Active Ulcerative 
Colitis in a Rando-
mized Controlled 
Trial.20
July 2015.
Randomized control 
trial.
Level 1
n = 63
Moayyedi, Paul
Patients with active 
ulcerative colitis 
(Mayo score > 4) 
without CDI.
Compare outcomes 
of FMT given 
weekly for 6 weeks 
in UC patients with 
water-enema pla-
cebo given weekly 
for 6 weeks.
• Remission of UC: Mayo score < 2.
• Change in Mayo score.
9/27 (33%) patients in FMT enema group 
achieved remission.
Remission rates of UC did not differ between 
placebo group and FMT group.
Table 2 (continue). Clinical evaluation of fecal microbiota transplantation.
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First author
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criteria
Objective Measures Findings
Transfer of Intes-
tinal Microbiota 
From Lean Donors 
Increases Insulin 
Sensitivity in Indivi-
duals With Metabo-
lic Syndrome.3
October 2012
Randomized 
control trial
Level 1
n = 18, 
each group 
with 9
Vrieze, Anne
Male 
Caucasians 
with BMI 
> 30 and 
fasting 
plasma 
glucose 
> 5.6
Mean 
age: 47
Assess effect of lean 
donor FMT in obese 
patient with meta-
bolic parameters 
after 6 weeks.
Determine alte-
rations of intes-
tinal microbiome 
composition with 
allogeneic and 
autologous FMT.
Quantify diversity 
of microbiomes in 
microbiome samples
• Insulin sensitivity 
via hyperinsuline-
mic-euglycemic clamp
• Intestinal microbio-
me composition as 
determined by sequen-
cing and analysis
• Fecal short chain 
fatty acids
• Simpson 
reciprocal index of 
diversity
Obese subjects had increased insulin sensitivity and bacterial diversity after FMT, 
especially those related to butyrate production; total amount of bacteria was not 
significantly different
• 16 different groups of bacteria were increased with allogeneic FMT compared to before FMT
o Phylum: Firmicutes. Roseburia intestinalis; Ruminococcus bromii, R. callidus, 
R. lactaris*, ∏ R. gnavus; Sporobacter termitidis; Eubacterium siraeum; Anaero-
truncus colihominis; Clostridium nexile*, C. ramosum, C. symbosium, C. sphenoi-
des*;  Aneurinibacillus; Coprobacillus catenaformis*; Dorea formicigenerans*.
o Phylum: Proteobacteria. Oxalobacter formigenes*
• Of these 16, six (*) groups were at significantly different levels between the two FMT groups.
Diversity was increased post-FMT in patient samples; this was found to be asso-
ciated with improved insulin sensitivity.
High-Throughput 
DNA Sequence 
Analysis Reveals 
Stable Engraftment 
of Gut Microbiota 
Following Trans-
plantation of 
Previously Frozen 
Fecal Bacteria.26
March 2013
Prospective 
case series
Level: 2
n = 3
Hamilton, 
Matthew J
Fecal sam-
ples of CDI 
patients 
treated 
with frozen 
FMT before 
and after 
transplan-
tation
Observe changes 
in microbiome 
composition 
of CDI patients 
before and after 
FMT.
Compare donor 
composition to 
FMT recipient 
composition.
Assess temporal 
changes in 
microbiome 
composition up 
to 4 months.
• Genetic sequen-
cing of DNA from 
fecal samples
• Operational 
taxonomic units 
(OTUs) derived 
from sample 
sequences
• Shannon diversi-
ty index
OTUs from the three patients were low pre-FMT with an average of 296 and high post-
FMT with an average of 948 for all three patients.
Donor samples were characterized by higher levels of Bacteroidetes and Firmicu-
tes and lower levels of Proteobacteria, Actinobacteria and Verrucomicrobia
• Phylum: Bacteroidetes
o Bacteroidaceae; Bacteroides; Porphyromonadaceae; Parabacteroides; Rikenellaceae; Alistipes
• Phylum: Firmicutes
o Lachnospiraceae; Ruminococcaceae; Erysipelotrichaceae; Unclassified Clostridiales
Pre-FMT samples were characterized by higher levels of Proteobacteria and Firmicutes, with con-
siderable variation among the three patients; notably, many of the bacteria were classified into:
• Phylum: Proteobacteria
o Enterobacteriaceae. Klebsiella; Salmonella; Escherichia/Shigella; Kyuvera; Parasutterella
• Phylum: Firmicutes
o Lactobacillaceae. Lactobacillus; Veillonellaceae. Veillonella; Enterococcus; Erysipelotrichaceae
Post-FMT samples were characterized by increases in levels of Bacteriodetes and 
Firmicutes, with profiles similar to donor samples.
Post-FMT composition remained stable in patients 1 and 2 over the course of obser-
vation and resembled donor and initial profiles.
Post-FMT composition in patient 3 was dynamic; 20 days post-FMT the composi-
tion resembled donor profiles but at subsequent time points the composition of 
Proteobacteria (especially genus: Escherichia/Shigella) shifted:
• Day 28: 10%, day 36: 50%, day 68: 18%, day 90: 28%
This was attributed to development and treatment with antibiotics of urinary tract infec-
tion in patient 3; post-FMT composition was not regained within the observation period.
Microbiota Dyna-
mics in Patients 
Treated with 
Fecal Microbiota 
Transplantation 
for Recurrent 
Clostridium difficile 
Infection.2
November 
2013
Prospective 
case series
Level 2
n = 14
Song, Yang
Patients 
with three 
recurren-
ces of C. 
difficile co-
litis treated 
with FMT 
therapy.
Donors 
were 
chosen by 
patients.
Note: one 
treated 
patient 
relapsed 
and suc-
cessfully 
re-treated 
with FMT.
Mean age: 
62.7
F: 12, M: 2
Infer changes in 
the microbiome 
composition 
before and after 
FMT therapy at 
several discrete 
time points
• Genetic se-
quencing of fecal 
samples from both 
FMT recipient and 
donor 
• Samples 
analyzed for 
operational 
taxonomic units 
(OTUs); each OTU 
is the equivalent 
to one taxonomic 
species
o 14 donor 
samples
o 8 donor samples 
after FMT
o 11 patient sam-
ples pre-FMT
o 17 samples from 
8 of the treated 
patients post-FMT
• Relative abun-
dance of specific 
taxa of bacterial 
species using 
Metastats
• Diversity as in-
ferred by Shannon 
index of diversity
1321 OTUs identified; 65% of these were unique to both post-FMT and donor groups; 
35% were not identified in the pre-FMT samples.
OTUs increased significantly after FMT procedure as compared to before procedu-
re; equated to an increase in microbial diversity (Shannon index of diversity and 
Wilcoxon rank sum, p<0.01).
No difference in diversity was noted between donors and post-FMT groups.
• In the patient with relapse, the measured diversity was low relative to healthy donor 
samples; upon re-treatment, this was corrected.
• The composition of the microbiome of the relapse patient was similar to that of 
other post-FMT patients and donor compositions.
• Due to the short nature of the relapse, authors hypothesized that the existence or lack 
of existence of specific microbiome colonizers reflective of long term CDI and short CDI.
Bacteria from 3 taxonomic orders, all from two total phyla, altered in relative 
abundance; post-FMT samples were near but not exactly matching donor samples
• Phylum: Firmicutes
o Clostridiales. Lachnospiraceae; Peptostreptococcaceae; Ruminococcaceae
o Lactobacillales. Enterococcaceae; Streptococcaceae
• Phylum: Proteobacteria
o Enterobacteriales. Klebsiella
The variation in these was as follows after FMT:
• Lactobacillales: significant decrease. Clostridiales: significant increase. Enterobacteriales: decrease
Streptococcus members were found in higher amounts in the post-FMT group than 
the donor group, implicating a role in the increased susceptibility of post-FMT 
patients to recurrence of C. difficile colitis; not statistically significant.
Patients’ intestinal profiles were analyzed temporally; variation of profiles was not 
found as analyzed by two different statistical methods to 20 weeks.
The diversity of the post-FMT group was stable and comparable up to a year in 
patients; authors described the changes over time as shifting in the direction of an 
already established profile and increasing in concentration of existing bacteria rather 
than shifting to alternate profiles as measured by mean UniFrac phylogenetic values.
Species and Genus 
Level Resolution 
Analysis of Gut 
Microbiota in 
Clostridium Difficile 
Patients Following 
Fecal Microbiota 
Transplantation.25
April 2014
Case series
Level: 2
n = 3
Shankar, 
Vijay
Patients 
with 
recurrent 
CDI with 
failure of 
treatment 
with anti-
biotics.
Assess changes 
of microbiome 
composition 
in CDI patients 
before and after 
FMT, and com-
pared to donors 
through time.
• Genetic 
sequencing and 
microarray analysis 
of fecal samples 
from recipient pre- 
and post-FMT and 
donor, confirmed by 
fluorescence in situ 
hybridization (FISH).
• Stability through 
time assessed by 
Spearman corre-
lation.
• Changes in 
diversity of micro-
biome assessed by 
Shannon index.
Pre-FMT samples had low levels of diversity, whereas donor and post FMT samples 
had higher levels of diversity as assessed by the Shannon diversity index; after 
day 3, post-FMT profiles converged to a composition to donor.
Temporally, the microbiome composition of patients remained stable with a Spearman 
correlation of 0.87 over 4 months of sampling; no major shifts in composition occurred.
Specific constituents were identified as abundant in samples; these were divided into 
groups with the phyla and genera listed below.
• Donor samples, group 1: an average of the abundance in all these genera was 
<1% in pre-FMT samples and higher in donor and post-FMT samples at 3%
o Bacteriodetes. Bacteriodes
o Firmicutes. Holdemania; Coprococcus; Faecalibacterium; Subdoigranulum; Roseburia; Blautia; Papillibacter.
o Other: Akkermansia
• Abundant in all pre-FMT patient samples but not in donor samples, group 2: an average of the abun-
dance in all these genera was 6-12% in pre-FMT samples and lower in donor and post-FMT samples at 0%
o Firmicutes. Veillonella; Lactobacillus
o Proteobacteria. Escherichia/Shigella; Raoultella; Enterobacter
• Abundant in some pre-FMT patient samples, group 3: in the indicated patients below, elevated 
levels of these genera were 4-30%, and all were less than 3% in post-FMT and donor samples
o Firmicutes. Zymophilus (2 + 3); Streptococcus (1 + 2); Enterococcus (3)
o Proteobacteria. Klebsiella (2 + 3); Haemophilus (1)
• Inconsistently abundant in samples, group 4: Bifidobacterium levels were elevated in samples 
both pre-FMT (patient 1, 18%) and donor (patient 3, 13%), inconsistently, while levels of Lactococcus 
varied, but not as dramatically elevated in donor samples (patient 1 and 3, 2%) and pre-FMT (3%)
o Actinobacteria. Bifidobacterium. Firmucutes. Lactococcus
On a species level, the trends followed the genera; specific species that increased after FMT:
• Bacteriodes fragilis, B. ovatus, B. uniformis; Faecalibacterium prausnitzii; Clostridium bart-
lettii; Dorea longicatena; Holdemania filiformis; Roseburia intestinalis; Ruminococcus obeum
Species that were detected in high quantities in pre-FMT samples:
• Bifidobacterium adolescentis; Escherichia coli; Klebsiella pneumonia; Bifidobac-
terium adolescentis; Enterococcus faecium;  Lactobacillus salivarius
Table 3. Bacterial shifts in intestinal microbiome composition.
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author
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Recovery of the 
Gut Microbiome 
following Fecal 
Microbiota Trans-
plantation.11
June 2014
Prospective 
case series
Level: 2
n = 14
Seekatz, 
Anna M
Patients 
with 
C.difficile 
infection 
with two 
prior in-
fections of 
C. difficile 
colitis and 
failed 
antibiotic 
therapy.
Mean age: 
57.4
F: 11, M: 3
Infer changes in 
the microbiome 
composition 
before and after 
FMT therapy 
with regards 
to CDI.
• Genetic se-
quencing of fecal 
samples from both 
FMT recipient and 
donor.
• Samples analyzed 
for operational 
taxonomic units 
(OTUs); each OTU 
is the equivalent 
to one taxonomic 
species
o 14 samples pre-FMT 
o 14 donor samples
o 16 post-FMT samples
• Relative abundan-
ce of specific taxa 
of bacterial species 
using Metastats.
• Diversity as in-
ferred by Shannon 
index of diversity.
1796 OTUs identified; these represented 164 genera – post-FMT and donor composition 
was more similar than as compared to pre-FMT levels as calculated by a similarity index.
The bacteria that had the most significant compositional changes were:
• Phylum: Firmicutes. Ruminococcaceae: Faecalibacterium, Subdoligranulum, Flavonifac-
tor; Lachnospiracea: Blautia, Lachnospiracea, Anerostipes, Clostridium XIVb, Roseburia, 
Dorea, Coprococcus, Clostridium XIVa; Acidaminococcaceae: Acidaminococcus; Clostri-
diaceae: Clostridium sensu stricto; Streptococcaceae: Streptococcus; Lactobacillaceae: 
Lactobacillus; Peptostreptococcaceae: Clostridium XI; Enterococcaceae: Enterococcus; 
Veillonellaceae:  Dialister; Erysipelotrichaceae: Erysipelotrichaceae, Clostridium XVIII.
• Phylum: Bacteriodetes. Bacteriodaceae: Bacteriodes; Rikenellaceae: Alistipes; 
Porphyromonadaceae: Parabacteroides, Barnesiella; Prevotellaceae: Prevotella.
• Phylum: Proteobacteria. Enterobacteriaceae: Cronobacter; Sutterellaceae: 
Parasutterella; Pasteurellaceae.
Pre-FMT composition heavily favored Proteobacteria species
• An average of 48.2% of OTUs – Cronobacter and another member (unclassified) 
of Enterobacteriaceae composed to bulk of OTUs pre-FMT
• Post-FMT, these levels dropped to 0.12% of the composition of samples
Post-FMT and donor samples had elevated levels of OTUs from Firmicutes and Bacteroidetes
• Firmicutes
o Major components: Blautia, Lachnospiraceae, an unclassified member, and 
Faecalibacterium; OTU composition: Donor: 65.4%, post-FMT: 51.6%
• Bacteroidetes
o OTU composition: Donor: 32.8%, post-FMT: 32.2%; Major components: Bacteroides and Alistipes
Post-FMT, diversity was found to increase in samples from CDI patients but not to 
the level found in donor samples; possible partial recovery diversity post-FMT
Alteration of 
Intestinal Dysbiosis 
by Fecal Microbiota 
Transplantation 
Does not Induce 
Remission in Pa-
tients with Chronic 
Active Ulcerative 
Colitis.4
September 
2013
Prospective 
case series
Level: 2
n = 6
Kump, 
Patrizia
Patients 
with 
chronic, 
active UC 
refrac-
tory to 
treatment; 
patients 
were on re-
gimens of 
5-ASA and 
steroids.
Mean age: 
36.2
F: 3, M: 3 
Assess the 
potential for FMT 
in the patient 
population of 
chronic, active 
UC.
Note: no pre-
FMT antibiotic 
was used.
• UC score judged 
with Mayo score
• Fecal calprotectin 
levels and serum 
CRP
• Genetic analysis 
of FMT samples
• Patterns of 
response to 
FMT indicated 
by microbiome 
composition via 
UniFrac distance to 
assess similarity
• Diversity as in-
ferred by Shannon 
index of diversity
No patient achieved remission in the follow-up interval of 90 days; at 1 year, 50% had remission.
2 weeks post-FMT, all patients reported a decrease in stool frequency; 4/6 patients by day 30 increased.
No change in fecal calprotectin or serum CRP
FMT had a temporary increase in diversity, peaking at day 7 and declining thereafter.
4 patterns of response were observed:
1. Microbiome converged to donor (3/6 patients)
2. Microbiome converged to donor then reversed
3. Microbiome changed unrelated to donor/self
4. Microbiome resembled donor before FMT and changes were minor; the authors noted that 
the 4th pattern of response was noteworthy; this patient had the best response to FMT.
Compositional analysis of microbiome profiles showed a decreasing abundance of Proteobacte-
ria from day 0 to day 90 and an increasing colonization by Bacteroides and Firmicutes. 
12 bacterial species of 64 identified represented 85% of OTUs in all samples; 3 of these bacte-
rial families had statistically significant changes post-FMT in stool samples and 5 in mucosal 
samples– changes are given baseline to day 7 to day 30 to day 90 assessed via Metastas
Stool samples
• Phylum: Bacteriodetes
o Bacteroidaceae: increase from 0.9% to 12.2% to 13.5% to 23.0% to 19.6%
• Phylum: Firmicutes
o Lactobacillales: decrease from 5.7% to 0.1% (day 7) to 0.1%. Enterococcaceae
• Phylum: Proteobacteria
o Enterobacteriales. Enterobacteriaceae: decrease from 25.8% to 3.3% (day 30) to 0.1%
Mucosal samples
• Phylum: Firmicutes
o Lactobacillales: decrease from 6.5% to 0.2% (day 7) to 0.1%. Enterococcaceae
o Bacillales: increase from 0% to 1.2%. Turicibacteraceae
• Phylum: Bacteriodetes
o Bacteriodales. Bacteroidaceae: increase from 1.5% to 16.0% to 11.9% to 18.2% to 15.0%
o Clostridiales family XIII: increase from 0% to 1.0%
• Phylum: Proteobacteria
o Enterobacteriaceae: decrease from 20.7% to 0.8% (day 30) to 0.1%
Temporal Bacterial 
Community Dyna-
mics Vary Among 
Ulcerative Colitis 
Patients After Fecal 
Microbiota Trans-
plantation.24
September 
2013
Prospective 
case series
Level = 2
n = 5
Angelberger, 
Sieglinde
Patients 
with chro-
nic UC
Mean age: 
34.3
F: 2, M: 3
Analyze changes 
in microbiome 
composition over 
time in UC pa-
tients after FMT.
Relate clinical 
correlation of 
symptoms to 
microbiome.
• Remission
• Mayo endoscopic 
score
• Genetic analysis 
of microbiome 
composition using 
OTUs
o Bacteria were 
sampled at times 
points at follow up 
to track changes 
in composition
• Similarity as 
determined by Uni-
Frac distance and 
Pearson correlation
• QIIME software 
parameters for 
diversity
o Alpha and beta 
diversity
No patients achieved remission in a follow up of 12 weeks; one patient had an 
improvement in the Mayo score and two experienced worsening.
A transient shift to donor microbiota after FMT was detected, but the longevity of this shift was highly va-
riable among patients; the single patient that responded to FMT had persistent shift 12 weeks to follow up.
• Pre-FMT samples had low levels of phylum diversity
o Elevated levels of: Enterobacteriaceae, Enterococccaceae
o Depressed levels of: Lachnospiraceae, Ruminococcaceae, Bacteroidaceae
• Post-FMT samples of UC patients were taken at several time points and varied 
significantly from patient to patient
o Samples from patients 1, 3, and 5 shifted to donor profile
∏ Samples from patient 3, the lone responder, had a similar compositional profile to donor 12 weeks post-FMT; OTUs 
related four species were found to stabilize at different time points throughout the observation in this patient
• Clostridium spiroforme
• Roseburia faecis
• Bacteroides ovatus
• Faecalibacterium prausnitzii. Samples from patients 1 and 5 had marked 
dissimilarity to donor after 2-4 weeks 
o Samples from patient 4 did not indicate alteration in microbiome to donor 
profile; data on patient 2 was unavailable
The dynamics of the microbiome composition were shifting, and certain groups of bacteria 
peaked at distinct times, suggesting colonization of the gut to be a slow, iterative process.
Reset of a Critically 
Disturbed Microbial 
Ecosystem: Faecal 
Transplant in Recu-
rrent  Clostridium 
Difficile Infection.12
February 
2014
Retrospec-
tive case 
series (using 
data from 
NTR1177)
Level: 4
n = 9
Fuentes, 
Susana
Patients 
with CDI 
defined 
as at 
least one 
relapse 
while using 
antibiotic 
therapy 
and posi-
tive toxin 
assay.
Mean age: 
69.6
F: 18, M: 24
Analyze the 
microbiome 
composition of 
patients with 
recurrent CDI 
and the changes 
therein before 
and after FMT.
Assess temporal 
variation 
post-FMT in 
microbiome 
composition.
Determine a pre-
ferential donor 
composition for 
FMT by compari-
son of FMT from 
the same donor 
to a different 
donor.
Determine 
composition 
of microbiome 
specifically 
protective 
against CDI
• Genetic sequen-
cing via microarray 
of DNA isolated 
from fecal samples
• Shannon index of 
diversity
• Similarity index
• Networks of 
occurrence of 
as determined 
by Spearman 
correlation
• Pearson corre-
lation
• Microbiome com-
position as com-
pared to healthy, 
vancomycin-trea-
ted volunteers
FMT increased levels of diversity in CDI patients; this was maintained throughout the 
observation period of 70 days and increased to levels comparable to donors
Shifts in composition occurred immediately after FMT, and resembled donor composition.
• Pre-FMT samples had large levels of Proteobacteria species, as well as 3 to 50 
fold levels of bacteria related to Bacilli members, Lactobacillus plantarum, and 
Streptococcus intermedius; these levels dropped off after FMT
• Post-FMT, Bacteroidetes and butyrate-producing bacteria from Clostridium 
clusters IV and XIVa were increased
• 41% of the genera were significantly different between donor samples and pre-FMT samples
• This value dropped to 13% post-FMT at day 70
• Composition profiles remained stable after day 14 
Samples from donor 4 (D4) were used in FMT of 4 patients; these patients had 
similarity indices higher to each other than to patients that received FMT from 
other donors
• FMT recipients from D4 also had higher similarity at day 70 compared to 
their donor than FMT recipients from other donors, but this was not significant 
statistically
• Authors hypothesize some microbiome members may have properties that allow 
for such a shift; D4 samples expressed higher levels of Bacteroides
o B. intestinalis
o B. plebeius
o B. uniformis
Samples of CDI patients on vancomycin assessed against healthy volunteers on van-
comycin showed majorly decreased levels of Bacteroidetes and Firmicutes; levels of 
butyrate-producer Megasphaera elsdenii was also less in CDI patient samples
Table 3 (continue). Bacterial shifts in intestinal microbiome composition.
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results congruent with data regarding FMT in IBD thus far. Se-
ven of 23 (30.4%) patients who underwent healthy donor FMT 
had clinical remission of UC, as compared to 8 of 25 (32%) con-
trols who underwent autologous FMT. One secondary outcome 
examined clinical response defined by change in the SCCAI, 
finding 11 of 23 (47.8%) patients with donor FMT had some 
measurable response whereas 13 of 25 (52%) patients of au-
tologous transplantation also had some response. The adverse 
events noted in this randomized control trial were not signifi-
cant and resolved spontaneously within 2 days.21
Two published case series assessed FMT for the treatment of IBD 
in pediatric populations, with a mean age of 15.0.22,23 A total of 14 
patients treated between the two case series. Another case series 
examined outcomes of FMT for CDI in 3 patients with UC, noting 
remission of CDI but no effect of FMT on UC clinically.19 A pooled 
analysis on both FMT case series by Colman, et al., indicated a 
remission rate of 64.1% in these pediatric populations overall.5
Compositional analysis of the intestinal microbiome in 
therapeutic fecal transplantation
Many studies have linked compositional dysbioses of intestinal 
bacteria to a variety of disease states.1 While the evidence of FMT 
efficacy in the resolution of CDI and other conditions is becoming 
more validated through clinical intervention and observation, 
the exact therapeutic mechanisms of the procedure are not fully 
elucidated. With the overarching goal of FMT being alteration of 
these pathological states to a point to symbiotic homeostasis, 
understanding the changes and dynamics of bacterial flora after 
FMT has begun to shed light on the effects of the procedure.
The large driving force in clarifying the compositional chan-
ges of the human microbiome has been the advancement of 
analytical technology. At the turn of the century, the Human 
Microbiome Project was created to begin a categorization of the 
various niches of bacteria commensal to humans.1 Out of this 
came the development of 16S ribosomal sequencing, a method 
that sequences the hypervariable portion of the 16S portion 
of the 30S prokaryotic ribosomal RNA subunit. The high-throu-
ghput ability of the sequencing method created allowed for 
the development of catalogues of bacterial signatures across 
a number of body sites. Data from these catalogues has been 
used to generate operational taxonomic units (OTUs), small 
phylogenetic units clustered by sequence similarity. OTU clus-
ters generated from samples have been equated to species, 
and OTU analysis has allowed for characterization of taxonomic 
composition of samples.17
This compositional analysis has been used to characterize the 
intestinal microbiome and reveal on a more detailed level the 
bacterial alterations of FMT.
Compositional changes associated with fecal transplantation
Compositional analyses of data from the peri-FMT period have 
been performed on samples from patients with CDI, IBD, and 
metabolic syndrome in 8 studies.3,4,11,12,17,24-26 Findings are broad-
ly categorized by proportional changes in three phyla: Firmi-
cutes, Bacteroidetes, and Proteobacteria. Members of these 
phyla on the family, genus, and species level as documented 
in the literature are included in Table 3. Post-FMT, every study 
documented increases in members of Bacteriodetes and Firmi-
cutes in CDI samples. Members of Proteobacteria post-FMT in 
CDI patient samples were decreased in all studies. Findings in 
patients with UC were not generalizable, but were found to be 
less consistent than those of CDI.
Temporal changes in composition after fecal transplantation
Samples taken at various time points have allowed for the ob-
servation of the dynamics in the peri-FMT period. Microbiome 
profiles before and after FMT have characterized compositional 
changes in the phyla listed above. In addition to describing 
these changes, six studies sequenced and analyzed multiple 
samples a year past the FMT procedure.2,4,12,24-26
Dynamics of the microbiome after fecal transplantation in 
Clostridium difficile infection
Four studies in Table 3 examined alterations of bacterial flo-
ra in patients with CDI.2,12,25,26 Song, et al., did not find any 
significant alterations in proportions of compositional flora 
after 20 weeks.2 Shankar, et al., found stability in patient 
microbiomes after 4 months, with an increasing similarity of 
post-FMT samples to donor samples with time.25 Comparable 
results were demonstrated by Fuentes, et al., in patients after 
70 days, with samples post-FMT converging to donor profiles; 
particular donor profiles were also found to impart greater 
similarity post-FMT with time.12
Hamilton, et al, observed stability in two of three patients trea-
ted with FMT over 90 days.26 In their third patient, significant 
alterations were seen over the course of the study. These alte-
rations were found to coincide with patient dosing of antibio-
tics for treatment of a urinary tract infection. In this patient, a 
composition similar to the FMT donor was not regained in the 
observation period.
Dynamics of the microbiome after fecal transplantation in 
inflammatory bowel disease
Two studies characterized dynamics of bacterial flora in pa-
tients with IBD, specifically with UC.4,24 Kump, et al., described 
four patterns of changes in six patients with UC treated with 
FMT.4 In three of the treated patients, the intestinal microbiome 
converged to donor composition. Of the other treated patients, 
one patient had a microbiome composition convergence to do-
nor composition, but subsequent reversal. In another patient, 
compositional changes in the microbiome appeared to be unre-
lated to the pre-FMT composition or to the donor composition. 
In the last patient, pre-FMT bacterial composition and donor 
composition were similar, and changes post-FMT were minor. 
Compositional analysis of microbiome profiles showed a de-
creasing abundance of Proteobacteria from day 0 to day 90 and 
an increasing colonization by Bacteroides and Firmicutes. At 90 
days, none of the UC patients had remission of their disease, 
but at follow up one year post-FMT, three of the six treated 
patients had remission.4
Angelberger, et al., treated five patients suffering from UC with 
FMT and observed changes in the bacterial flora over the cour-
se of 12 weeks.24 A transient shift to donor microbiota after 
FMT was detected in patients, but the longevity of this shift 
was highly variable. Samples from three patients shifted to a 
composition resembling donor bacterial composition. Of these 
three patients, one patient had a similar compositional profile 
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to the donor 12 weeks post-FMT and experienced clinical be-
nefit of the FMT therapy. Samples from the other patients with 
donor shifts had marked dissimilarity to the donor after 2-4 
weeks. Other patients in the study did not have a compositio-
nal shift in their microbiome after FMT that resembled donor 
composition.24
Compositional diversity of microbiomes
Diversity of the bacterial communities found in samples from the 
peri-FMT period and from donors was measured via three primary 
modalities in studies assessed: the Shannon index of diversity, 
the Simpson index of diversity, and alpha and beta diversities.
Studies documenting shifts in diversity in CDI patients consis-
tently found increases in diversity after FMT therapy.2,11,12,15,25,26 
Additionally, diversity was found to increase to levels approa-
ching donor diversity over time. Vrieze et al., 2012 assessed 
FMT in patients with metabolic syndrome and also found di-
versity to be increased post-FMT in patient samples.3 This 
increase was found to be associated with improved insulin 
sensitivity. Diversity in microbiomes of patients with UC who 
underwent FMT were found to be varied. Kump et al., 2013 in-
dicated an initial increase in diversity immediately after FMT, 
but declining levels thereafter throughout the duration of the 
observation period.4 Angelberger et al., did not have clear 
metrics of diversity.24
Discussion
Fecal microbiota transplant as an effective therapy
Published clinical data assessing the clinical efficacy of FMT as 
a cure for CDI is well established in the reviewed studies. Cure 
rates ranged from 89-100%, and FMT was shown to be superior 
to antibiotics in a controlled trial in CDI patients. Additionally, 
no paper attributed any direct adverse outcomes of FMT. This 
was especially highlighted in patients with compromised im-
mune status, a population more at risk with such a procedure.
However, FMT was not as consistently successful in the treat-
ment of IBD, with much lower cure rates. The pathogenesis and 
disease characteristics of IBD, both Crohn’s and UC, differ signi-
ficantly from CDI. Specifically, both IBDs are chronic conditions 
characterized by high levels of inflammation with multifactorial 
and incompletely understood etiology, whereas CDI is intrinsi-
cally caused by an acute disruption of the microbiome, often 
precipitated by antibiotic use. Because FMT is associated with 
an acute restoration of a healthy microbiome composition, it 
may directly treat CDI. Alternatively, the variable response to 
FMT seen in patients with IBD indicates the acute therapeutic 
modality of FMT may not suit the chronicity of the disease.
To highlight this point, some remission of UC was documented 
over placebo in a trial that treated patients with several FMTs 
over weeks. Both 2015 randomized control trials of FMT in UC 
had modest cure rates and similar outcomes, despite different 
frequencies of serial FMTs, with one being once every three 
weeks for a total of two infusions and the other being weekly 
for six weeks.20,21 The multiple rounds of microbiome restora-
tion may have had some effect on the chronic inflammation of 
IBD. However, other trials without multiple rounds of FMT for 
the treatment of IBD did not have lesser cure rates than the 
randomized trial, casting doubt on this interpretation. 
Associations of fecal transplantation with clinical outcomes
The clinical variables by the papers reviewed examined age, sex, 
immune status, antibiotic regimen, CDI recurrence, gastric acid su-
ppression therapy, and patient perception of treatment.3,10,13-16,18,24 
Surprisingly, no correlation of FMT outcomes and variables were 
established other than with patient perception of health that was 
self-reported and is likely due to three factors. The first is the 
limited sample size of each study. Due to the emerging nature 
of therapeutic FMT, there are not a substantial number of FMT 
trials conducted to warrant establishment of patterns of clinical 
success. The second relates to study design. Currently, clinical 
researchers seek to establish the credibility of FMT as a viable and 
easy therapy, with more concern with the overall clinical outcomes 
and the microbiome shifts associated with FMT. Practically, after 
more research and trials on FMT have been conducted, objectives 
will shift to other clinical variables. The third reason there has 
been no concrete correlation of certain variables with outcomes 
is the high success rate of FMT in CDI. The vast majority of FMT 
trials have been conducted in patients with CDI, and, of these, 
few failures of resolution have been reported. These low failure 
rates coupled with the already small sample size in the studies 
reviewed leave little room for variables to be firmly tied to clinical 
success and failure.
Safety of fecal transplantation
The transplantation of fecal material from donor to recipient is, 
by definition, introduction of foreign biological material into a 
host. The transfer of bacteria raises the possibility of infection, 
particularly if the recipient is already in a diseased state. FMT 
in patients with systemic immune suppression, such as HIV/
AIDS, or patients on immunosuppressive drugs with solid organ 
allografts or inflammatory conditions such as rheumatoid ar-
thritis, could theoretically result in infection through the donor 
material. Kelly et al., 2014 concluded after a multicenter, retros-
pective case series of 80 patients that there was no increased 
risk of FMT in the immunocompromised after assessing adver-
se events, the nature of the events, and overall critical nature 
and complexity of said patients.13
Safety of the FMT procedure is partially warranted by rigorous 
donor screening, and while each center performing FMT has 
a slightly different protocol, communicable diseases are ge-
nerally paneled and screened. These include cytomegalovirus, 
hepatitis B and C, HIV, and syphilis serologically and C. diffici-
le, Salmonella, Shigella, Yersinia, E. coli, and Campylobacter. 
Stools are also tested for helminths and parasites.3,4,22 Much 
like any other transplantation protocol, standardization of FMT 
would allow for a more rigorous approach to its assessment 
and evaluation. As its prevalence increases, this becomes more 
of a necessity for the safety of patients undergoing FMT.
Alterations of bacterial flora in dysbiotic microbiomes
While a variety of diseases have been associated with micro-
biome dysbiosis, only a handful of these have been treated 
by FMT in a clinical trial, reviewed here. The alterations in the 
composition of microbiomes for metabolic syndrome, IBD, and, 
most thoroughly, CDI, have been documented in Table 3.
In lean donors, researchers observed an appreciable increase 
in insulin sensitivity in patients with metabolic syndrome in a 
randomized control trial.3 Interestingly, other metabolic para-
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meters measured were not altered, such as lipid profiles and 
body composition. In patients suffering from IBD treated with 
FMT, metrics to assess outcomes of FMT were mainly the Mayo 
score of severity for UC, patient-reported health scores, and 
endoscopy.4,5,16,18-20,22,24 FMT was not consistently associated with 
remission. In CDI, FMT has much evidence for its efficacy in the 
resolution of diarrhea.
The three phyla reported to have significant changes in these 
patient groups were Firmicutes, Bacteriodetes, and Proteobac-
teria. In all three FMT-treated disease states, members within 
these phyla shifted in similar directions.2–4,11,12,24–26
Firmicutes members Lachnospiraceae, Ruminococceae, Erysipe-
lotrichaceae, Peptostreptococcaceae, Veillonellaceae, Acidami-
nococcaceae, Streptococcaceae, Enterococcaceae, Lactobacilla-
ceae, and Clostridiaceae were found to be increased in more 
than one study.11,25,26 Bacteriodetes members Bacteriodaceae, 
Porphyromonadaceae, and Rikenellaceae were found to be in-
creased after FMT in more than one study.11,26 Proteobacteria 
members of Enterobacteriaceae were found to be decreased 
after FMT.2,4,11,24–26
These shifts were stable in successful therapeutic FMT, and 
declined in the majority of UC cases of IBD analyzed by stu-
dies. Particularly, the fact that stability of the typical post-FMT 
shifts persisted in the lone UC patient in the study by Angel-
berger et al., in 2013 supports this notion.24
Shortcomings of microbiome analysis in fecal transplantation
The major limitation of the compositional analyses was their 
inter-relatability. While having similar findings, each study had 
different metrics of data presentation. In particular, reporting 
by studies on specific species and its shifts were limited by the 
resolution of the analytic method used. Some studies were able 
to report genus- and family-level resolution, whereas others 
were able to report species-level resolution.3,4,11,12,17,24–26 As the 
technology of microbiome analysis advances, sequencing and 
analysis will become more standardized and distinct, allowing 
for more readily comparable data sets.
Another shortcoming of studies reviewed for microbiome analy-
sis was the small patient populations in each study. Increasing 
interest in FMT, as well as advances in technology will allow 
for larger populations of patients to undergo sequencing and 
compositional analysis, increasing the power of the findings of 
these studies.
Future perspectives
While the efficacy of FMT in CDI is fairly high, several studies 
remarked on the fact that no clinically proven optimal protocol 
exists. Variables of the procedure have been assessed briefly 
with no clinical impact, and further randomized control trials 
with larger populations are needed to properly assess the im-
pact of protocol variability on clinical outcomes.
Ample microbiome studies have provided evidence for links be-
tween dysbiotic gut bacteria and disease. As research in this field 
progresses, clinical trials of therapeutic FMT for diseases other 
than IBD, CDI, and metabolic syndrome can evaluate the true po-
tential of microbiome compositional alteration in clinical medicine.
Conclusion
FMT is slowly gaining traction as a treatment option for disease. 
Evidence backing its therapeutic value exists for CDI, but further 
elucidation of its effects in IBD and other diseases is required.
Dave AA, et al. Clinical Utility and Alterations in Bacterial Flora in Fecal Microbiome Transplantation
The International Journal of Medical StudentsInt J Med Students   •   2015  |  Sep-Dec  |  Vol  3  |  Issue 3 150
Review
References
1. Cho I, Blaser MJ. The Human Microbiome: at the interface of health and 
disease. Nat Rev Genet. 2012 Mar 13;13(4):260–70. 
2. Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, et al. 
Microbiota dynamics in patients treated with fecal microbiota transplanta-
tion for recurrent Clostridium difficile infection. PLoS ONE. 2013;8(11):e81330. 
3. Vrieze A, van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, et al. 
Transfer of intestinal microbiota from lean donors increases insulin sensitivity in 
individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913–6.e7. 
4. Kump PK, Gröchenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, 
et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation 
does not induce remission in patients with chronic active ulcerative colitis. 
Inflamm Bowel Dis. 2013 Sep;19(10):2155–65. 
5. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for in-
flammatory bowel disease: a systematic review and meta-analysis. J Crohns 
Colitis. 2014 Dec;8(12):1569–81.
6. Borody TJ, Campbell J, Torres M. Reversal of idiopathic thrombocytopenic 
purpura (ITP) with fecal microbiota transplantation (FMT) [abstract]. Am J 
Gastroenterol 2011; 106:S352.
7. Borody TJ, Nowak A, Torres M, Campbell J, Finlayson S, Leis S. Bacterio-
therapy in chronic fatigue syndrome: a retrospective review [abstract]. Am J 
Gastroenterol 2012; 107 (Suppl 1):S591–S592. (A1481).
8. Anathaswamy A. Fecal transplant eases symptoms of Parkinson’s. New 
Sci 2011;2796:8–9.
9. Borody TJ, Leis S, Campbell J. Fecal microbiota transplantation (FMT) in 
multiple sclerosis (MS) [abstract]. Am J Gastroenterol 2011; 106:S352.
10. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. Oral, 
capsulized, frozen fecal microbiota transplantation for relapsing Clostridium 
difficile infection. JAMA. 2014 Nov 5;312(17):1772–8. 
11. Seekatz AM, Aas J, Gessert CE, Rubin TA, Saman DM, Bakken JS, et al. 
Recovery of the gut microbiome following fecal microbiota transplantation. 
MBio. 2014;5(3):e00893–00814. 
12. Fuentes S, van Nood E, Tims S, Heikamp-de Jong I, ter Braak CJ, Keller JJ, 
et al. Reset of a critically disturbed microbial ecosystem: faecal transplant in 
recurrent Clostridium difficile infection. ISME J. 2014 Aug;8(8):1621–33. 
13. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. 
Fecal microbiota transplant for treatment of Clostridium difficile infection in 
immunocompromised patients. Am J Gastroenterol. 2014 Jul;109(7):1065–71.
14. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota 
transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile in-
fection. Clin Infect Dis. 2011 Nov;53(10):994–1002. 
15. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, 
et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N 
Engl J Med. 2013 Jan 31;368(5):407–15. 
16. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et 
al. Long-term follow-up of colonoscopic fecal microbiota transplant 
for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012 
Jul;107(7):1079–87. 
17. Dutta SK, Girotra M, Garg S, Dutta A, von Rosenvinge EC, Maddox C, et 
al. Efficacy of combined jejunal and colonic fecal microbiota transplantation 
for recurrent Clostridium difficile Infection. Clin Gastroenterol Hepatol. 2014 
Sep;12(9):1572–6. 
18. Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. 
Fecal microbiota transplant for relapsing Clostridium difficile infection using 
a frozen inoculum from unrelated donors: a randomized, open-label, contro-
lled pilot study. Clin Infect Dis. 2014 Jun;58(11):1515–22. 
19. Russell GH, Kaplan JL, Youngster I, Baril-Dore M, Schindelar L, Hohmann E, 
et al. Fecal transplant for recurrent Clostridium difficile infection in children 
with and without inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 
2014 May;58(5):588–92.
20. Moayyedi P, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, et al. 
Fecal Microbiota Transplantation Induces Remission in Patients With Active 
Ulcerative Colitis in a Randomized Controlled Trial. Gastroenterology. 2015 
Jul;149(1):102–9.e6. 
21. Rossen NG, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou 
A, et al. Findings From a Randomized Controlled Trial of Fecal Trans-
plantation for Patients With Ulcerative Colitis. Gastroenterology. 2015 
Jul;149(1):110–8.
22. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H Jr, et al. Safe-
ty, tolerability, and clinical response after fecal transplantation in children 
and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013 
Jun;56(6):597–601. 
23. Suskind DL, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via 
nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol 
Nutr. 2015 Jan;60(1):27–9.
24. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Pa-
pay P, et al. Temporal bacterial community dynamics vary among ulcerative 
colitis patients after fecal microbiota transplantation. Am J Gastroenterol. 
2013 Oct;108(10):1620–30.
25. Shankar V, Hamilton MJ, Khoruts A, Kilburn A, Unno T, Paliy O, et al. 
Species and genus level resolution analysis of gut microbiota in Clostridium 
difficile patients following fecal microbiota transplantation. Microbiome. 
2014;2:13. 
26. Hamilton MJ, Weingarden AR, Unno T, Khoruts A, Sadowsky MJ. High-throu-
ghput DNA sequence analysis reveals stable engraftment of gut microbiota 
following transplantation of previously frozen fecal bacteria. Gut Microbes. 
2013 Apr;4(2):125–35.
Dave AA, et al. Clinical Utility and Alterations in Bacterial Flora in Fecal Microbiome Transplantation
Acknowledgments
We would like to thank Dr. James P. Bruzik for his help and guidance in the preparation of this review.
Conflict of Interest Statement & Funding
The author has no funding, financial relationships or conflicts of interest to disclose.
Author Contributions
Conception and design the work/idea, Collect data/obtaining results, Analysis and interpretation of data, Write the manuscript, Critical 
revision of the manuscript, AD. Approval of the final version: AD, RR. Administrative or technical advice: RR
Cite as: 
Dave AA, Robson R. Clinical Utility and Alterations in Bacterial Flora in Fecal Microbiome Transplantation. Int J Med Students. 2015 Sep-
Dec;3(3):140-50.
